Lorlatinib Continuation Study

Summary

The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention

Timeline

Start

2021-12-28

Primary completion

2026-12-28

Completion

2026-12-28

Drugs

Indications